Consequences and treatment of ovarian failure after total body irradiation for leukaemia. 1989

M P Cust, and M I Whitehead, and R Powles, and M Hunter, and S Milliken
Academic Department of Obstetrics and Gynaecology, King's College School of Medicine and Dentistry, London.

OBJECTIVE To assess the incidence and severity of physical and psychosexual symptoms in young women due to ovarian failure caused by total body irradiation for leukaemia and the women's response to hormone treatment. METHODS Postal questionnaire and interview. METHODS Leukaemia unit of oncology hospital. METHODS Consecutive series of 46 English speaking women who had developed ovarian failure after total body irradiation and bone marrow transplantation as treatment for leukaemia. RESULTS Of the 36 responders, 33 reported some symptoms, vaginal dryness being the most common (29). This profoundly affected sexual function. Although 22 women had had sexual intercourse within six months after treatment, 16 were less interested in and 18 experienced difficulties with sexual intercourse. Anxieties about sterility, femininity, and appearance were common and reduced self confidence. Almost half reported that they had changed their social habits and restricted their social activities. Treatment seemed effective in abolishing symptoms in 24 women, but vaginal dryness remained a problem in three. Two women failed to respond and intercourse remained impossible. CONCLUSIONS Such patients are vulnerable and access to gynaecologists and endocrinologists soon after treatment would be valuable. The optimal treatment regimen and the long term benefits of treatment have yet to be established.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D010049 Ovarian Diseases Pathological processes of the OVARY. Disease, Ovarian,Diseases, Ovarian,Ovarian Disease
D010053 Ovary The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE. Ovaries
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014623 Vaginal Diseases Pathological processes of the VAGINA. Disease, Vaginal,Diseases, Vaginal,Vaginal Disease
D014916 Whole-Body Irradiation Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms. Radiation, Whole-Body,Total Body Irradiation,Irradiation, Total Body,Irradiation, Whole-Body,Whole-Body Radiation,Irradiation, Whole Body,Irradiations, Total Body,Irradiations, Whole-Body,Radiation, Whole Body,Radiations, Whole-Body,Total Body Irradiations,Whole Body Irradiation,Whole Body Radiation,Whole-Body Irradiations,Whole-Body Radiations
D015914 Estrogen Replacement Therapy The use of hormonal agents with estrogen-like activity in postmenopausal or other estrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, DYSPAREUNIA, and progressive development of OSTEOPOROSIS. This may also include the use of progestational agents in combination therapy. Hormone Replacement Therapy, Post-Menopausal,Postmenopausal Hormone Replacement Therapy,Replacement Therapy, Estrogen,Estrogen Progestin Combination Therapy,Estrogen Progestin Replacement Therapy,Estrogen Replacement,Replacement, Estrogen,Therapy, Estrogen Replacement,Estrogen Replacement Therapies,Estrogen Replacements,Hormone Replacement Therapy, Post Menopausal,Replacement Therapies, Estrogen,Replacements, Estrogen,Therapies, Estrogen Replacement

Related Publications

M P Cust, and M I Whitehead, and R Powles, and M Hunter, and S Milliken
February 1990, BMJ (Clinical research ed.),
M P Cust, and M I Whitehead, and R Powles, and M Hunter, and S Milliken
February 1990, BMJ (Clinical research ed.),
M P Cust, and M I Whitehead, and R Powles, and M Hunter, and S Milliken
July 1992, Bone marrow transplantation,
M P Cust, and M I Whitehead, and R Powles, and M Hunter, and S Milliken
October 1980, Radiography,
M P Cust, and M I Whitehead, and R Powles, and M Hunter, and S Milliken
March 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
M P Cust, and M I Whitehead, and R Powles, and M Hunter, and S Milliken
November 1983, British journal of haematology,
M P Cust, and M I Whitehead, and R Powles, and M Hunter, and S Milliken
September 1980, The British journal of radiology,
M P Cust, and M I Whitehead, and R Powles, and M Hunter, and S Milliken
February 1989, Transplantation proceedings,
M P Cust, and M I Whitehead, and R Powles, and M Hunter, and S Milliken
April 1986, Lancet (London, England),
M P Cust, and M I Whitehead, and R Powles, and M Hunter, and S Milliken
January 1982, Scandinavian journal of haematology,
Copied contents to your clipboard!